ResMed completed the acquisition of Noctrix Health for $340 million on June 3, 2026, integrating its Nidra TOMAC therapy for restless legs syndrome into ResMed's sleep medicine ecosystem. This acquisition marked the first portfolio exit for investor Angelini Ventures. Additionally, ResMed acquired VirtuOx in May 2025, enhancing its capabilities in independent sleep and respiratory diagnostic testing services. In fiscal Q3 2026, ResMed reported net revenue of $1.43 billion, reflecting an 11% year-over-year increase, driven by strong demand for sleep devices, masks, and residential care software. The company also reported strong Q3 operating cash flow of $554 million, indicating improved profitability compared to the previous year. ResMed's adjusted earnings per share for Q3 increased to $2.86 from $2.37 a year earlier, beating consensus expectations. Furthermore, ResMed's gross margin expanded by 290 basis points year-over-year in Q3 FY2026, supported by lower component costs and supply chain efficiencies.